Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FH-TCR-TMSLN |
| Synonyms | |
| Therapy Description |
FH-TCR-TMSLN are autologous T-lymphocytes engineered to express a T-cell receptor (TCR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (J Clin Oncol 41, no. 4_suppl (February 01, 2023) TPS779), NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FH-TCR-TMSLN | FH-TCR TMSLN | MSLN Immune Cell Therapy 10 | FH-TCR-TMSLN are autologous T-lymphocytes engineered to express a T-cell receptor (TCR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (J Clin Oncol 41, no. 4_suppl (February 01, 2023) TPS779), NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04809766 | Phase I | Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine | Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |